Updated results from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for Janus kinase inhibitor-naive patients with myelofibrosis Meeting Abstract


Authors: Mascarenhas, J. O.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; Lucchesi, A.; Oh, S.; Kuykendall, A. T.; Patriarca, A.; Alvarez-Larran, A.; Mesa, R.; Kiladjian, J. J.; Talpaz, M.; Harris, M.; Kays, S. K.; Li, Q.; Brown, B.; Jegg, A. M.; Harrison, C.; Rampal, R.
Abstract Title: Updated results from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for Janus kinase inhibitor-naive patients with myelofibrosis
Meeting Title: 66th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 144
Issue: Suppl. 1
Meeting Dates: 2024 Dec 7-10
Meeting Location: San Deigo, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2024-11-05
Start Page: 3178
End Page: 3180
Language: English
ACCESSION: WOS:001412581600034
DOI: 10.1182/blood-2024-193193
PROVIDER: wos
Notes: Meeting Abstract -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Raajit Kumar Rampal
    338 Rampal